About Us

Overview

  • CEO/CTO

    Heechung Kwon

    30+ years of experience in Gene Therapy, Virus Engineering, HSV and Oncolytic Virus Expert

  • Founded

    The New Drug project started in 2005 and GCM is founded in 2019

  • Major Description

    The first startup of the New Drug Division at KIRAMS. GCM engineers viruses to deliver genes to disease cells and kill the cell to treat human diseases

Gencellmed Inc.

Gencellmed is a portmanteau of Gene + Cell + Medicine

Organizationional Chart

History

2023

  • Selected as a Military Service-Designated entities (Research institute)

2022

  • Successful completion of TIPS Program organized by Ministry of SMEs and Startups (MSS) in Korea
  • oHSV Adapter Patent granted (KR)(US)
  • Double Targeting Patent granted (KR)

2021

  • Series A Investment completed (KRW 2 billion)
  • Selected to Conduct National New Medicine Development Project organized by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, Ministry of health and Welfare
  • gH Adapter Patent granted (KR)
  • Signed MOU to Develop a Combined Modality Therapy of Next-Generation Immuno-Oncolytic with Y Biologics Inc.

2020

  • The Second Research Institute opened at KIRAMS
  • Certified as the Venture Business in Korea
  • Certified as the Corporate Affiliated Research Institute of KIRAMS

2019

  • Gencellmed Inc. established(Designated as the First Venture Business for Developing New Medicine at KIRAMS)
  • Received Operating Right of Special Permission Related to the U.S. Patent on Adapter Technologies
  • The First Research Institute opened at KIRAMS
  • Selected for the TIPS Program organized by Ministry of SMEs and Startups (MSS) in Korea